Clinical Research Directory

Inclusion Criteria: * Stage I-III breast cancer (including inflammatory and newly diagnosed, or locally recurrent but not metastatic breast cancer being treated with curative intent) * 18-85 years old * Scheduled to receive anthracycline based chemotherapy with or without estrogen antagonist aromatase inhibitors (anastrozole \[Arimidex\], letrozole \[Femara\], exemestane \[Aromasin\]). * Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2 * Able to walk at least 2 blocks without chest pain, dyspnea or fainting * Participants in other ongoing clinical trials are eligible for this study * Participants must be able to speak, read, and understand English sufficiently to provide informed consent and complete all study-related procedures and assessments. Exclusion Criteria: * Uncontrolled hypertension (systolic blood pressure \>190 mm Hg or diastolic blood pressure \>100 mm Hg) * A recent history of alcohol or drug abuse * Inflammatory conditions such as lupus or inflammatory bowel disease, or another medical condition that might compromise safety or successful completion * Type I diabetes * Contraindications to Magnetic resonance imaging (MRI) (example: iron-based metal implants, cerebral aneurysm clip) * Current treatment with empagliflozin at the time of screening or enrollment * Significant ventricular arrhythmias (PVC) (\>20 PVCs/min due to gating difficulty) * Atrial fibrillation with uncontrolled ventricular response (\>130 bpm) * Acute myocardial infarction within 28 days * Claustrophobia * Pregnancy * Those unable to provide informed consent * Moving within 6 mos. of enrollment * Individuals who are unable to speak, read, or understand English sufficiently to provide informed consent and complete study procedures will be excluded.